USG bought 30 million doses of the (now named) Jynneos vaccine over the past 20 years, frozen in bulk. Where did they go?

Then the US government ordered 7 million more doses since 2020.  But CDC keeps saying the supply is limited.  Limited to whom, by whom?

From today’s Wall Street Journal:

“Given the current limited
supply of vaccine, CDC recom-
mends temporarily changing
some behaviors that may in-
crease a person’s risk of being
exposed,” an agency spokes-
woman said.

Why is it that the CDC can never tell us the truth?

Below is from a July 15, 2022 press release issued by the vaccine manufacturer:

U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

• Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS^® vaccine, bringing deliveries in 2022 and 2023 to a total of nearly 7 million doses
• Filling capacity is being expanded with a U.S. based contract
  manufacturer who will fill the vaccines using existing bulk vaccine from
  previous orders from BARDA
• Tech transfer to the contract manufacturer and manufacturing planned for 2022
• Company upgrades its financial guidance for 2022

COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic
A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced
Research and Development Authority (BARDA), part of the Office of the
Assistant Secretary for Preparedness and Response at the U.S. Department
of Health and Human Services, has ordered an additional 2.5 million
doses of liquid-frozen JYNNEOS^®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.

The new order follows two previous orders from BARDA in June and July
2022 for 500,000 and 2.5 million doses respectively which, together
with an order from BARDA in 2020 for 1.4 million doses, will bring the
total deliveries in 2022 and 2023 to nearly 7 million doses.

This additional order will be filled at a U.S. based contract
manufacturer using bulk vaccine already manufactured and invoiced under
previous contracts with BARDA and currently stored at Bavarian Nordic. A
tech transfer of the process to the contract manufacturer will begin
immediately, with the aim to manufacture all doses under this contract
in 2022.

Paul Chaplin, President and CEO of Bavarian Nordic said: “Expanding
our manufacturing capabilities into the United States allows Bavarian
Nordic to deliver more monkeypox vaccines to meet the immediate
worldwide demand for JYNNEOS. This quick response to a serious health
crisis is only possible because of the U.S. government’s diligent
long-term planning for their national preparedness.”